JPI 547

Drug Profile

JPI 547

Alternative Names: JPI-547

Latest Information Update: 17 Mar 2016

Price : $50

At a glance

  • Originator Jeil Pharmaceutical
  • Class
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors; Tankyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Colorectal cancer

Most Recent Events

  • 17 Mar 2016 Preclinical trials in Colorectal cancer in South Korea (unspecified route) prior to March 2016 (Jeil Pharmaceutical's pipeline, March 2016)
  • 17 Mar 2016 JPI 547 is available for licensing as of 17 Mar 2016 (Jeil Pharmaceutical's website, March 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top